Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment-Reference-Cited by-同舟云学术

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment

Published:2021-05 Issue: Volume:149 Page:61-72
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Provencio Mariano^ORCID,Serna-Blasco Roberto^ORCID,Franco Fabio,Calvo Virgina,Royuela Ana^ORCID,Auglytė Milda,Sánchez-Hernández Alfredo,de Julián Campayo María,García-Girón Carlos,Dómine Manuel,Blasco Ana,Sánchez José M.,Oramas Juana,Bosch-Barrera Joaquim^ORCID,Sala María Á.,Sereno María,Ortega Ana L.,Chara Luis,Hernández Berta,Padilla Airam,Coves Juan,Blanco Remedios,Balsalobre José,Mielgo Xabier,Bueno Coralia^ORCID,Jantus-Lewintre Eloisa,Molina-Vila Miguel Á.,Romero Atocha^ORCID

Funder

European Commission

Comunidad de Madrid

Boehringer Ingelheim GmbH

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. American Society of Clinical Oncology. Lung cancer – non-small cell: statistics | Cancer.Net n.d. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.

2. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations;Sequist;J Clin Oncol,2008

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

5. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol,2016

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making;Cancer Management and Research;2024-07

2. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

3. Prognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancer;Future Oncology;2023-11-15

4. Neoadjuvant therapy in non-small cell lung cancer;Critical Reviews in Oncology/Hematology;2023-10

5. Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer;Journal of Cancer Research and Clinical Oncology;2023-09-28